CordenPharma completes API process bay for category 4 compounds

By Melissa Fassbender contact

- Last updated on GMT

CordenPharma Colorado's new highly potent API process bay. (Image: CordenPharma)
CordenPharma Colorado's new highly potent API process bay. (Image: CordenPharma)

Related tags: United states

This week CordenPharma announced the completion of its new highly potent API process bay for category 4 compounds.

The addition was completed at the company’s Boulder, Colorado facility, which is equipped to handle highly potent compounds up to OEB Level 5 spanning development to commercial-scale.

With the new process bay, the facility can now handle a range of chemistries and unit operations with flexible and scalable components up to multi-kg batches.

(Image: CordenPharma)
(Image: CordenPharma)

According to Brian McCudden, President and Managing Director of CordenPharma Colorado, the first cGMP campaign is scheduled to be completed in early Q4 2016.

The investment comes on the heels of several facility improvements, including expanded development capabilities (CTD2) at its Plankstadt (Germany) facility, and further expansion of capabilities in handling sterile oncology drug products at CordenPharma Latina (Italy).

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars